Loading briefing details...
News Brief
By: PointLine Media Research & Editorial Team
October 29, 2026
This transition marks a pivotal shift toward localized medical manufacturing, reducing dependency on distant supply chains. By prioritizing regional production, Hallstat enhances quality control and delivery reliability. This strategic move not only prepares the company for a successful U.S. market entry but also sets a new operational standard for infection-prevention technology.
Hallstat, a nurse-founded medical device innovator, is strategically transitioning the manufacturing of its proprietary Foley Catheter System to the United States and nearby regions. This initiative aims to bolster supply chain resilience, reduce operational costs, and expedite delivery times for healthcare providers. By bringing production closer to the U.S. market, Hallstat ensures tighter oversight and consistent adherence to rigorous quality control standards as it prepares for an upcoming national launch.
The Hallstat Foley System is engineered to address the critical challenge of catheter-associated urinary tract infections (CAUTIs). Developed by nurse and CEO Bruce Huici, the system integrates advanced features like the MicroTip for reduced irritation, BACTIStat antimicrobial tubing, the BermeoValve to prevent backflow, and 100% medical-grade silicone construction. Each component reflects clinical insights gathered directly from the bedside to improve patient safety and recovery outcomes.
Currently, Hallstat is conducting a comprehensive evaluation of potential manufacturing partners to ensure alignment with ISO 13485 standards and scalable production capabilities. While no agreements are finalized, this shift represents a commitment to accountability and excellence. As a certified Minority Business Enterprise, Hallstat remains dedicated to delivering high-quality, nurse-designed solutions that empower clinicians and protect patients from hospital-acquired infections.